Year in Review : Reflecting on Recent Evidence with an Eye to the Future of Lung Cancer Management
WebcastFaculty
OVERVIEW
Year in Review : Reflecting on Recent Evidence with an Eye to the Future of Lung Cancer Management is organized by Physicians Education Resource, LLC (PER) and would be held during Feb 28, 2017 - Feb 28, 2018.
The target audience for this medical event for oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals (HCPs) interested in the treatment of lung cancer may also participate. This CME Conference has been approved with a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives are :
• State the design of clinical trials that have utilized prognostic and predictive markers in the treatment of patients with advanced forms of lung cancer.
• Discuss key findings from recent clinical trials conducted in the setting of advanced NSCLC.
• Explain recent efficacy and safety results in the context of evolving treatment paradigms in the field and applicability to clinical practices.
• Describe planned/ongoing clinical trials intended to address remaining unanswered clinical questions in the field of advanced NSCLC management.
Additional details will be posted as soon as they are available.
The target audience for this medical event for oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals (HCPs) interested in the treatment of lung cancer may also participate. This CME Conference has been approved with a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives are :
• State the design of clinical trials that have utilized prognostic and predictive markers in the treatment of patients with advanced forms of lung cancer.
• Discuss key findings from recent clinical trials conducted in the setting of advanced NSCLC.
• Explain recent efficacy and safety results in the context of evolving treatment paradigms in the field and applicability to clinical practices.
• Describe planned/ongoing clinical trials intended to address remaining unanswered clinical questions in the field of advanced NSCLC management.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links